Neurocrine's NBI-1117568 meets Phase 2 primary endpoint; 7.5-point PANSS reduction vs placebo

NEUROCRINE BIOSCIENCES INC

20 mg once-daily dose met primary endpoint: placebo-adjusted PANSS reduction of 7.5 points (p=0.011, effect size 0.61) at Week 6.
Dose also statistically significant on CGI-S, Marder positive and negative symptom scores.
NBI-’568 well tolerated; no weight gain vs placebo; GI events low; discontinuation rates similar to placebo.
Company plans to advance NBI-’568 into Phase 3 development in schizophrenia in early 2025.
Other doses (40 mg, 60 mg QD, 30 mg BID) did not reach statistical significance on primary endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.